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Background: Loss of cadherin 1 (CDH1) expression, which is normally involved in cell adhesion and maintenance
of tissue architecture, is a hallmark of invasive lobular carcinoma (ILCA). Because hereditary cancers may require
different risk reduction, counseling and treatment options than sporadic cancer, it is critical to determine the
prevalence of germline CDH1 mutations in patients with ILCA.
Methods: All patients with ILCA (n = 100) previously enrolled in the Clinical Breast Care Project were identified.
Genomic DNA was isolated from peripheral blood samples and DNA variants were detected for each exon of
CDH1 using high-resolution melting technology followed by direct sequencing.
Results: Within the 100 samples screened, four nonsynonymous variants were detected: A592T in one Hispanic
patient, A617T in two patients, both African American, P825L in a Causasian patient whose grandmother had
stomach cancer, and G879S in a Caucasian patient. Further evaluation of A617T in an additional 165 African
American patients found that 11 patients, none with ILCA, carried this variant including one patient who was
homozygous for the variant.
Conclusions: CDH1 mutations are infrequent in patients with ILCA, and the variants that were detected have been
classified as non-pathogenic. These data suggest that ILCA does not have a significant hereditary component and
do not support CDH1 gene mutation testing in patients with ILCA.
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Breast cancer represents a group of diseases, with differ-
ent histological, molecular and clinical characteristics,
including tumor growth patterns, with at least 17 differ-
ent histological types currently described [1]. Invasive
lobular carcinoma (ILCA), the second most common
histological type, accounts for 8-14% of all breast cancers
[2,3]. ILCA is histologically characterized by a loss of
cellular adhesion, resulting in growth of single cells or
cells arranged in a single file or “Indian lines” [3,4].
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unless otherwise stated.is more difficult to detect by palpation or mammography
[5,6]. Compared to invasive ductal carcinoma (IDCA),
ILCA is more often diagnosed at a later age, more likely
to be hormone receptor positive, larger, diploid, and
HER2, p53 and EGFR negative. ILCA has a distinctive
pattern of metastasis, with a propensity to metastasize to
the peritoneum, gastrointestinal tract and ovaries. Despite
its favorable characteristics, disease-free and overall survival
did not differ between ILCA and IDCA [7].
One of the hallmarks of ILCA is the loss or altered
expression of cadherin 1 (CDH1, GenBank: AB025105.1).
CDH1 is a member of the classical/type I cadherin family
that is involved in maintaining cellular adhesion. CDH1 in-
teracts with members of the catenin family; this complex
then links with actin molecules to provide cellular adhesionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phenotype characteristic of not only ILCA but also heredi-
tary diffuse gastric cancer (HDGC). In fact, ILCA is a fre-
quent finding in HDGC families, with a 39% lifetime risk of
developing ILCA in HDGC families with CDH1 germline
mutations [9].
The frequency of CDH1 germline mutations in fam-
ilies with HDGC is 25-30% [10]. Determination of the
frequency of CDH1 mutations in patients with ILCA is
crucial; clinically, the diffuse nature of ILCA makes early
detection more challenging [5] and increased risk for bi-
lateral disease impacts the choice of surgical approaches.
In addition, presence of hereditary CDH1 mutations will
impact risk assessment, family counseling and screening,
for both breast and stomach malignancies. To this end,
CDH1 was screened for germline mutations in a popula-
tion of patients with ILCA.Methods
All patients included in this study were enrolled in the
Clinical Breast Care Project (CBCP) between 2001 and
2010. Blood samples were collected with approval from
the Walter Reed National Military Medical Center Human
Use Committee and Institutional Review Board. All sub-
jects voluntarily agreed to participate and gave written in-
formed consent. Clinical information, including family
cancer history, was obtained for all CBCP participants using
questionnaires designed by and administered under the
auspices of the CBCP.Table 1 PCR primers and annealing temperature for each of t

















Cycling conditions were: 95.0°C for two minutes, followed by 50 cycles of 94.0°C for
followed by a single cycle of 94.0°C for 30 seconds and then 20.0°C for 30 seconds.The CBCP database was queried to identify all female
patients diagnosed with ILCA. Family history of cancers
was self-described by the patients and included data for
both primary and secondary relatives. Diagnosis of every
specimen was performed by a dedicated breast patholo-
gist from hematoxylin and eosin (H&E) stained slides;
staging was performed using guidelines defined by the
AJCC Cancer Staging Manual seventh edition [11]. In
addition, to determine the frequency of the A617T variant
in African American women, all female African Americans
with invasive breast cancers such as IDCA and tumors with
mixed IDCA and ILCA features were identified.
Genomic DNA was isolated from blood clots using the
GentraClotspin and Puregene DNA purification kits
(Qiagen, Valencia, CA). Polymerase chain reaction (PCR)
primers were designed to flank CDH1 exons 1–15 and the
coding region of exon 16 (Table 1). PCR reactions were
performed on 25 ng genomic DNA using Lightscanner
Master Mix (BioFire Defense, Salt Lake City, UT) and
analyzed on the LightScanner System following manu-
facturer’s protocols. For those samples with a variant
detected by the LightScanner, PCR products were
purified using ExoSAP-IT For PCR Product Clean-up
(Affymetrix, Santa Clara, CA), and sequenced using
BigDye terminator v 3.1 cycle sequencing kits (Life
Technologies, Inc, Carlsbad, CA). The resulting prod-
ucts were sequenced on a 3730xl DNA Analyzer (Life
Technologies, Inc, Carlsbad, CA) and sequence files
were analyzed using Sequencher 4.10.1 (Gene Codes
Corporation, Ann Arbor, MI).he 16 exons

















30 seconds and the specified annealing temperature for 30 seconds,
Table 2 Summary of variants in patients with ILCA
SNP ID SNP effect Number of patients with
variant (n = 100)
Ethnicitya
c.71C > G 5’ UTR 3 W
345G > A Synonymous 1 W
531 + 10G >
C
Intronic 9 W
933C > G Synonymous 1 AA
1680G > C Synonymous 1 W
A592T Missense 1 HS
A617T Missense 1 AA
1896C > T Synonymous 2 AA
2076 T > C Synonymous 46 W, AA, HS,
NA
1937-13 T > C Intronic 6 W
95971C > T Synonymous 6 W
P825L Missense 1 W
G879S Missense 1 W
101193C > A Synonymous 2 AA
aEthnicity groups are: AA = African American, HS = Hispanic, NA = Native
American, W = White.
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SNP genotyping assay C__32307311_10 (Life Technolo-
gies, Inc, Carlsbad, CA) using 10 ng of DNA; reactions
were amplified in duplicate and genotypes (TT, TC or
CC) were determined using the ABI PRISM® 7000 Se-




Of the 100 patients with ILCA, six had a self-reported
history of gastric or stomach cancer in primary or sec-
ondary members of their family. None of the patients
had a personal history of any type of cancer other than
ILCA. The average age at diagnosis was 61.7 years
(range 44–70 years). The majority of patients were
Caucasian (83%), with early-stage (86%) and ER + HER2-
(93%) lobular carcinomas. Thirty-two percent of the pa-
tients had a family history of breast cancer, defined as at
least two primary or secondary relatives having been di-
agnosed with breast cancer at any age, while 20% of pa-
tients had bilateral breast cancer, similar to that seen in
other ILCA populations [7]. Two of the patients, both
diagnosed with stage IIIC luminal A ILCA have died of
disease.
Mutation results
No nonsense or splice site mutations were detected in
any of the 100 genomic DNAs evaluated. A number of
SNPs were detected in multiple individuals, including
seven synonymous variants, two intronic variants and
one variant in the 5’ UTR (Table 2). Four missense mu-
tations were identified including private variant P825L,
detected in a 62 year old white woman whose grand-
mother had stomach cancer, A592T in a 51 year-old
white woman, A617T in two African Americans, both
post-menopausal, and G879S in an 81 year-old white
woman.
With the identification of A617T in two African
American women, the variant was assessed in a panel of
genomic DNA samples from 165 additional African
American women with IDCA or mixed features of IDCA
and ILCA. Ten women were carriers of the minor (T)
allele and one additional patient, an African American
woman diagnosed with with IDCA at age 71, was homo-
zygous for the minor allele. The frequency of the T allele
in this population was similar to that reported in dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=
33935154) where it has been detected only in Sub-Saharan
African and African American populations.
Discussion
Identification of patients with hereditary predisposition to
breast cancer is critical for optimum clinical management.Identification of carriers of causative mutations can assist in
risk assessment and risk reduction, as well as in family
counseling. In addition, hereditary cancers may have differ-
ent phenotypes, requiring different treatment regimens. For
example, patients with BRCA1 mutations are at risk for
both bilateral breast disease as well as ovarian carcinoma;
thus, women with BRCA1-associated cancers may be of-
fered bilateral mastectomy and/or oophorectomy and may
derive more benefit from PARP inhibitors compared to pa-
tients with sporadic breast cancer [12]. Patients with both
hereditary and sporadic forms of ILCA may benefit from
targeted therapeutics such as the use of FGFR1 inhibitors
that block survival pathways and reverse tamoxifen resist-
ance [13], however, those with hereditary ILCA may, as
those with BRCA1 and BRCA2 mutations, be subjected to
increased screening for bilateral disease, offered risk reduc-
tion strategies, as well encouraged to undergo prophylactic
gastrectomy [14].
The frequency of potentially causative mutations in
this study was low, with no instances of splice site or
nonsense mutations detected. Only 5% (5/100) of pa-
tients had missense mutations. Under current guidelines
in which genetic testing for BRCA1 and BRCA2 mutation
is recommended for women with estimated probabilities of
having a germline mutation ≥10% [15], genetic testing for
CDH1 mutations in patients with ILCA would not be
warranted. In addition, the clinical importance of the
variants detected is unclear. To determine the patho-
genicity of these variants, the pubmed database (http://
www.ncbi.nlm.nih.gov/pubmed/) was searched for any
citations that included these variants. In addition, the
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database (http://cancer.sanger.ac.uk/cancergenome/pro-
jects/cosmic/) was searched. To our knowledge, variants
P825L and G879S have not been documented as causative
mutations in the literature, although a single instance of
the P825L variant in a lung tumor was reported in the
COSMIC database. Functional assessment of A592T sug-
gests this variant is likely tolerable and non-pathogenic
[16]. The A617T variant has been detected in a patient with
endometrial cancer [17] and in two female African
American patients with diffuse gastric cancer [18]. Trans-
fection of CHO cells with CDH1 carrying the A617T
variant resulted in an epithelial phenotype with extensive
cell-to-cell contacts with membranous E-cadherin and β-
catenin staining similar to that in wild-type cells [19]. Data
from our study supports A617T as being a non-pathogenic
variant; 10/165 African American women with IDCA and
one with mixed IDCA and ILCA were carriers of the minor
allele. In addition, one 71 year-old woman with IDCA was
homozygous for the minor allele. The 6.7% minor allele
frequency for A617T detected in our patient samples is
identical to that reported in dbSNP for African American
populations; thus this variant likely represents a non-
pathogenic SNP specific to individuals with African ances-
try. In addition, we performed a SIFT (Sorting Intolerant
From Tolerant) [20] analysis for the four non-synonymous
variants. A592T, A617T and G879S were classified as toler-
able variants, while P825L was predicted to be intolerable.
Our ability to detect mutations may be limited by the
technical approach employed. Large deletions may not
be detected by high-resolution melting analysis or direct
sequencing of amplified products, however, the reported
frequency of large-scale deletions in HDGC families is
low (3.8%) [21], thus it is not likely that many of the
ILCA patients have an undetected deletion. In addition,
genomic DNA samples from family members were not
collected, thus, it was not possible in this study to deter-
mine if the variants tracked with disease status. Finally,
identification of patients with a family history of gastric
cancer was based on self-reporting of cancer within
first- and second-degree family members by the patient
and ages at diagnosis were not provided. Of the 100 pa-
tients with ILCA, six had a single self-reported family
member with stomach or gastric cancer, thus, the major-
ity of these patients may not have a family history of
HDGC.
Conclusions
In our data of patients with ILCA unselected for age at
diagnosis or family history of breast cancer, the mutation
frequency was low – four missense mutations, only one
of which (P825L) has been predicted to be pathogenic -
in five individuals. These patients were recruited from a
breast, rather than gastroenterology clinic, and thus themutational frequency and spectrum differs based on
presence or absence of a significant family history of
HDGC. A previous study of 318 women with ILCA di-
agnosed <45 years or with a family history of breast
cancer found no deletions or truncating mutations and
of the six detected non-synonymous mutations, only
four were found to be pathogenic, for a mutation fre-
quency of 1.3% [22]. Together, these data suggest that
the frequency of germline mutations in patients with
ILCA is low, and screening for CDH1 mutations in this
population is not warranted.
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